The solution to this seeming paradox—called lead-time bias—is immediately obvious. Using survival as an end point for a screening test is flawed because early detection pushes the clock of diagnosis backward. Hope’s tumor and Prudence’s tumor possess exactly identical biological behavior. But since doctors detected Hope’s tumor earlier, it seems, falsely, that she lived longer and that the screening test was beneficial.
